CA3076809A1 - Devices, systems and methods for biomarker analysis - Google Patents
Devices, systems and methods for biomarker analysisInfo
- Publication number
- CA3076809A1 CA3076809A1 CA3076809A CA3076809A CA3076809A1 CA 3076809 A1 CA3076809 A1 CA 3076809A1 CA 3076809 A CA3076809 A CA 3076809A CA 3076809 A CA3076809 A CA 3076809A CA 3076809 A1 CA3076809 A1 CA 3076809A1
- Authority
- CA
- Canada
- Prior art keywords
- instances
- sample
- sequence
- minutes
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title abstract description 502
- 239000000090 biomarker Substances 0.000 title description 38
- 238000004458 analytical method Methods 0.000 title description 24
- 150000007523 nucleic acids Chemical class 0.000 abstract description 594
- 102000039446 nucleic acids Human genes 0.000 abstract description 583
- 108020004707 nucleic acids Proteins 0.000 abstract description 583
- 239000012472 biological sample Substances 0.000 abstract description 207
- 230000001605 fetal effect Effects 0.000 abstract description 68
- 238000004891 communication Methods 0.000 abstract description 45
- 230000008774 maternal effect Effects 0.000 abstract description 32
- 230000035935 pregnancy Effects 0.000 abstract description 24
- 210000003754 fetus Anatomy 0.000 abstract description 14
- 239000000523 sample Substances 0.000 description 478
- 210000002593 Y chromosome Anatomy 0.000 description 381
- 210000004027 cell Anatomy 0.000 description 254
- 238000003199 nucleic acid amplification method Methods 0.000 description 247
- 230000003321 amplification Effects 0.000 description 245
- 239000002773 nucleotide Substances 0.000 description 237
- 125000003729 nucleotide group Chemical group 0.000 description 236
- 239000008280 blood Substances 0.000 description 183
- 210000004369 blood Anatomy 0.000 description 182
- 238000012360 testing method Methods 0.000 description 175
- 239000013615 primer Substances 0.000 description 153
- 108091034117 Oligonucleotide Proteins 0.000 description 145
- 239000000047 product Substances 0.000 description 136
- 239000000306 component Substances 0.000 description 120
- 102000053602 DNA Human genes 0.000 description 113
- 108020004414 DNA Proteins 0.000 description 113
- 239000003153 chemical reaction reagent Substances 0.000 description 105
- 230000027455 binding Effects 0.000 description 102
- 210000002381 plasma Anatomy 0.000 description 95
- 239000012634 fragment Substances 0.000 description 85
- 238000001514 detection method Methods 0.000 description 83
- 239000012530 fluid Substances 0.000 description 78
- 210000003040 circulating cell Anatomy 0.000 description 67
- 230000000670 limiting effect Effects 0.000 description 64
- 108090000623 proteins and genes Proteins 0.000 description 61
- 239000012491 analyte Substances 0.000 description 59
- 238000003556 assay Methods 0.000 description 47
- 230000002068 genetic effect Effects 0.000 description 45
- 210000000349 chromosome Anatomy 0.000 description 41
- 238000006243 chemical reaction Methods 0.000 description 38
- 238000012163 sequencing technique Methods 0.000 description 38
- 238000012545 processing Methods 0.000 description 35
- 102000004169 proteins and genes Human genes 0.000 description 33
- 108091061744 Cell-free fetal DNA Proteins 0.000 description 30
- 210000002700 urine Anatomy 0.000 description 30
- 239000013060 biological fluid Substances 0.000 description 29
- 230000001413 cellular effect Effects 0.000 description 29
- 239000000463 material Substances 0.000 description 29
- 239000011148 porous material Substances 0.000 description 27
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 26
- 230000000295 complement effect Effects 0.000 description 26
- 230000003862 health status Effects 0.000 description 26
- 108090000765 processed proteins & peptides Proteins 0.000 description 26
- 238000000926 separation method Methods 0.000 description 26
- 238000011901 isothermal amplification Methods 0.000 description 25
- 239000012528 membrane Substances 0.000 description 25
- 238000003860 storage Methods 0.000 description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 23
- 210000002966 serum Anatomy 0.000 description 23
- 239000007787 solid Substances 0.000 description 23
- 238000007397 LAMP assay Methods 0.000 description 21
- 201000010099 disease Diseases 0.000 description 21
- 210000003296 saliva Anatomy 0.000 description 20
- 239000011159 matrix material Substances 0.000 description 19
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 18
- 238000001914 filtration Methods 0.000 description 18
- 239000002751 oligonucleotide probe Substances 0.000 description 18
- 239000000126 substance Substances 0.000 description 18
- 102000018120 Recombinases Human genes 0.000 description 17
- 108010091086 Recombinases Proteins 0.000 description 17
- 239000002245 particle Substances 0.000 description 17
- 230000032258 transport Effects 0.000 description 17
- 230000003169 placental effect Effects 0.000 description 16
- 238000000137 annealing Methods 0.000 description 15
- 150000003384 small molecules Chemical class 0.000 description 15
- 238000012549 training Methods 0.000 description 15
- 239000003155 DNA primer Substances 0.000 description 14
- 208000015181 infectious disease Diseases 0.000 description 14
- 238000012125 lateral flow test Methods 0.000 description 13
- 239000011859 microparticle Substances 0.000 description 13
- 206010028980 Neoplasm Diseases 0.000 description 12
- 230000006037 cell lysis Effects 0.000 description 12
- 108091092240 circulating cell-free DNA Proteins 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 230000012953 feeding on blood of other organism Effects 0.000 description 12
- 239000003550 marker Substances 0.000 description 12
- 108091093088 Amplicon Proteins 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 11
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 11
- 241000124008 Mammalia Species 0.000 description 11
- 239000000427 antigen Substances 0.000 description 11
- 108091007433 antigens Proteins 0.000 description 11
- 102000036639 antigens Human genes 0.000 description 11
- 230000009089 cytolysis Effects 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 230000003252 repetitive effect Effects 0.000 description 11
- 150000001413 amino acids Chemical class 0.000 description 10
- -1 antibodies Proteins 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 10
- 238000010438 heat treatment Methods 0.000 description 10
- 210000000265 leukocyte Anatomy 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 238000006073 displacement reaction Methods 0.000 description 9
- 210000001182 human Y chromosome Anatomy 0.000 description 9
- 230000002934 lysing effect Effects 0.000 description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 description 8
- 108700032475 Sex-Determining Region Y Proteins 0.000 description 8
- 102100022978 Sex-determining region Y protein Human genes 0.000 description 8
- 239000002458 cell surface marker Substances 0.000 description 8
- 238000001816 cooling Methods 0.000 description 8
- 230000007613 environmental effect Effects 0.000 description 8
- 230000004049 epigenetic modification Effects 0.000 description 8
- 239000003446 ligand Substances 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 102100034343 Integrase Human genes 0.000 description 7
- 108060004795 Methyltransferase Proteins 0.000 description 7
- 208000012902 Nervous system disease Diseases 0.000 description 7
- 210000001766 X chromosome Anatomy 0.000 description 7
- 239000011324 bead Substances 0.000 description 7
- 210000001124 body fluid Anatomy 0.000 description 7
- 239000010839 body fluid Substances 0.000 description 7
- 230000015556 catabolic process Effects 0.000 description 7
- 238000006731 degradation reaction Methods 0.000 description 7
- 230000001973 epigenetic effect Effects 0.000 description 7
- 230000033001 locomotion Effects 0.000 description 7
- 239000002105 nanoparticle Substances 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 210000003462 vein Anatomy 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 208000023275 Autoimmune disease Diseases 0.000 description 6
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 6
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 6
- 206010020751 Hypersensitivity Diseases 0.000 description 6
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 6
- 101150108975 Rhd gene Proteins 0.000 description 6
- 101710082933 Single-strand DNA-binding protein Proteins 0.000 description 6
- 210000000601 blood cell Anatomy 0.000 description 6
- 239000000975 dye Substances 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 238000007672 fourth generation sequencing Methods 0.000 description 6
- 229910052737 gold Inorganic materials 0.000 description 6
- 239000010931 gold Substances 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 230000005291 magnetic effect Effects 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 102000040430 polynucleotide Human genes 0.000 description 6
- 108091033319 polynucleotide Proteins 0.000 description 6
- 239000002157 polynucleotide Substances 0.000 description 6
- 238000003825 pressing Methods 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 230000011664 signaling Effects 0.000 description 6
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 5
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 5
- 101000845189 Homo sapiens Testis-specific Y-encoded protein 1 Proteins 0.000 description 5
- 102000018697 Membrane Proteins Human genes 0.000 description 5
- 108010052285 Membrane Proteins Proteins 0.000 description 5
- 108010047956 Nucleosomes Proteins 0.000 description 5
- 206010060862 Prostate cancer Diseases 0.000 description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000000692 anti-sense effect Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000002759 chromosomal effect Effects 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 210000001808 exosome Anatomy 0.000 description 5
- 210000003722 extracellular fluid Anatomy 0.000 description 5
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 5
- 230000002452 interceptive effect Effects 0.000 description 5
- 208000030159 metabolic disease Diseases 0.000 description 5
- 239000002070 nanowire Substances 0.000 description 5
- 210000001623 nucleosome Anatomy 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 210000002826 placenta Anatomy 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 108020004635 Complementary DNA Proteins 0.000 description 4
- 230000030933 DNA methylation on cytosine Effects 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 108700011259 MicroRNAs Proteins 0.000 description 4
- 108091093037 Peptide nucleic acid Proteins 0.000 description 4
- 229930182558 Sterol Natural products 0.000 description 4
- 102100031283 Testis-specific Y-encoded protein 1 Human genes 0.000 description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 4
- 208000030961 allergic reaction Diseases 0.000 description 4
- 238000002820 assay format Methods 0.000 description 4
- 230000001363 autoimmune Effects 0.000 description 4
- 238000010804 cDNA synthesis Methods 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000007850 fluorescent dye Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 229910021389 graphene Inorganic materials 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 238000009597 pregnancy test Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 210000003765 sex chromosome Anatomy 0.000 description 4
- 238000010008 shearing Methods 0.000 description 4
- 150000003432 sterols Chemical class 0.000 description 4
- 235000003702 sterols Nutrition 0.000 description 4
- 210000004243 sweat Anatomy 0.000 description 4
- 210000001138 tear Anatomy 0.000 description 4
- 230000036266 weeks of gestation Effects 0.000 description 4
- 238000012070 whole genome sequencing analysis Methods 0.000 description 4
- 102100028550 40S ribosomal protein S4, Y isoform 1 Human genes 0.000 description 3
- 108091023037 Aptamer Proteins 0.000 description 3
- 108010042407 Endonucleases Proteins 0.000 description 3
- 108060002716 Exonuclease Proteins 0.000 description 3
- 101000696103 Homo sapiens 40S ribosomal protein S4, Y isoform 1 Proteins 0.000 description 3
- 101000964566 Homo sapiens Zinc finger Y-chromosomal protein Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108091005461 Nucleic proteins Proteins 0.000 description 3
- 108091081021 Sense strand Proteins 0.000 description 3
- 102100040802 Zinc finger Y-chromosomal protein Human genes 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 230000003190 augmentative effect Effects 0.000 description 3
- 238000002869 basic local alignment search tool Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000001369 bisulfite sequencing Methods 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000002860 competitive effect Effects 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 102000013165 exonuclease Human genes 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 238000013467 fragmentation Methods 0.000 description 3
- 238000006062 fragmentation reaction Methods 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 238000000464 low-speed centrifugation Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000011987 methylation Effects 0.000 description 3
- 238000007069 methylation reaction Methods 0.000 description 3
- 239000002679 microRNA Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000000135 prohibitive effect Effects 0.000 description 3
- 238000010384 proximity ligation assay Methods 0.000 description 3
- 238000011897 real-time detection Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 208000004124 rheumatic heart disease Diseases 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 239000002689 soil Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000003371 toe Anatomy 0.000 description 3
- 108091005703 transmembrane proteins Proteins 0.000 description 3
- 102000035160 transmembrane proteins Human genes 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- 210000000605 viral structure Anatomy 0.000 description 3
- 102100024341 10 kDa heat shock protein, mitochondrial Human genes 0.000 description 2
- 229920001621 AMOLED Polymers 0.000 description 2
- 208000035657 Abasia Diseases 0.000 description 2
- 108010077805 Bacterial Proteins Proteins 0.000 description 2
- 208000019838 Blood disease Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 108091029523 CpG island Proteins 0.000 description 2
- 102100031780 Endonuclease Human genes 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 102100028504 Homeobox protein TGIF2LY Human genes 0.000 description 2
- 101000837834 Homo sapiens Homeobox protein TGIF2LY Proteins 0.000 description 2
- 101000759895 Homo sapiens Testis-specific Y-encoded protein 2 Proteins 0.000 description 2
- 206010020608 Hypercoagulation Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 102000005954 Methylenetetrahydrofolate Reductase (NADPH2) Human genes 0.000 description 2
- 108010030837 Methylenetetrahydrofolate Reductase (NADPH2) Proteins 0.000 description 2
- 102000002233 Myelin-Oligodendrocyte Glycoprotein Human genes 0.000 description 2
- 108010000123 Myelin-Oligodendrocyte Glycoprotein Proteins 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 108091093105 Nuclear DNA Proteins 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 102100024994 Testis-specific Y-encoded protein 2 Human genes 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 108700029634 Y-Linked Genes Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 239000012805 animal sample Substances 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000000712 assembly Effects 0.000 description 2
- 238000000429 assembly Methods 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000012875 competitive assay Methods 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 108010046025 early pregnancy factor Proteins 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 108010091897 factor V Leiden Proteins 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 239000003365 glass fiber Substances 0.000 description 2
- 238000003505 heat denaturation Methods 0.000 description 2
- 208000014951 hematologic disease Diseases 0.000 description 2
- 208000018706 hematopoietic system disease Diseases 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 2
- 210000003917 human chromosome Anatomy 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000004973 liquid crystal related substance Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000006249 magnetic particle Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000007481 next generation sequencing Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000005059 placental tissue Anatomy 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000002987 primer (paints) Substances 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 230000003075 superhydrophobic effect Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 201000005665 thrombophilia Diseases 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 238000011179 visual inspection Methods 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000002351 wastewater Substances 0.000 description 2
- RBSXHDIPCIWOMG-UHFFFAOYSA-N 1-(4,6-dimethoxypyrimidin-2-yl)-3-(2-ethylsulfonylimidazo[1,2-a]pyridin-3-yl)sulfonylurea Chemical compound CCS(=O)(=O)C=1N=C2C=CC=CN2C=1S(=O)(=O)NC(=O)NC1=NC(OC)=CC(OC)=N1 RBSXHDIPCIWOMG-UHFFFAOYSA-N 0.000 description 1
- LBCZOTMMGHGTPH-UHFFFAOYSA-N 2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCO)C=C1 LBCZOTMMGHGTPH-UHFFFAOYSA-N 0.000 description 1
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 102000014461 Ataxins Human genes 0.000 description 1
- 108010078286 Ataxins Proteins 0.000 description 1
- 241000713838 Avian myeloblastosis virus Species 0.000 description 1
- 241000157302 Bison bison athabascae Species 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008025 Cerebellar ataxia Diseases 0.000 description 1
- 108010059013 Chaperonin 10 Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 108091029430 CpG site Proteins 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 108050009160 DNA polymerase 1 Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 108010036364 Deoxyribonuclease IV (Phage T4-Induced) Proteins 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 241000193385 Geobacillus stearothermophilus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 208000003807 Graves Disease Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- 108091029795 Intergenic region Proteins 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 108091092878 Microsatellite Proteins 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 208000026072 Motor neurone disease Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 101710147059 Nicking endonuclease Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 240000005809 Prunus persica Species 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101710146873 Receptor-binding protein Proteins 0.000 description 1
- 206010049101 Rectal discharge Diseases 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 101150059736 SRY gene Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- UNKYOXKQMHLGPW-UHFFFAOYSA-N Urobilin IXalpha Natural products CCC1=C(C)C(=O)NC1CC2=NC(=Cc3[nH]c(CC4NC(=O)C(=C4C)CC)c(C)c3CCC(=O)O)C(=C2C)CCC(=O)O UNKYOXKQMHLGPW-UHFFFAOYSA-N 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 208000001455 Zika Virus Infection Diseases 0.000 description 1
- 208000035332 Zika virus disease Diseases 0.000 description 1
- 208000020329 Zika virus infectious disease Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- SMEGJBVQLJJKKX-HOTMZDKISA-N [(2R,3S,4S,5R,6R)-5-acetyloxy-3,4,6-trihydroxyoxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O)OC(=O)C)O)O SMEGJBVQLJJKKX-HOTMZDKISA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- 238000013473 artificial intelligence Methods 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 108091092259 cell-free RNA Proteins 0.000 description 1
- 230000010267 cellular communication Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003283 colorimetric indicator Substances 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- XZTWHWHGBBCSMX-UHFFFAOYSA-J dimagnesium;phosphonato phosphate Chemical compound [Mg+2].[Mg+2].[O-]P([O-])(=O)OP([O-])([O-])=O XZTWHWHGBBCSMX-UHFFFAOYSA-J 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 230000008995 epigenetic change Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 108010052305 exodeoxyribonuclease III Proteins 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical class O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000007421 fluorometric assay Methods 0.000 description 1
- 239000013568 food allergen Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 102000045506 human TSPY1 Human genes 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000006607 hypermethylation Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000002440 industrial waste Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000012482 interaction analysis Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 201000000564 macroglobulinemia Diseases 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 108091064355 mitochondrial RNA Proteins 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000006618 mitotic catastrophe Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000006855 networking Effects 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 1
- 230000006610 nonapoptotic cell death Effects 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002523 pancreas lymphoma Diseases 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 239000012521 purified sample Substances 0.000 description 1
- APTZNLHMIGJTEW-UHFFFAOYSA-N pyraflufen-ethyl Chemical compound C1=C(Cl)C(OCC(=O)OCC)=CC(C=2C(=C(OC(F)F)N(C)N=2)Cl)=C1F APTZNLHMIGJTEW-UHFFFAOYSA-N 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000004557 single molecule detection Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- 239000010454 slate Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 description 1
- 229960002871 tenoxicam Drugs 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 208000032521 type II spinal muscular atrophy Diseases 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- KDCCOOGTVSRCHX-UHFFFAOYSA-N urobilin Chemical compound CCC1=C(C)C(=O)NC1CC1=C(C)C(CCC(O)=O)=C(C=C2C(=C(C)C(CC3C(=C(CC)C(=O)N3)C)=N2)CCC(O)=O)N1 KDCCOOGTVSRCHX-UHFFFAOYSA-N 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
- C12N15/1017—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by filtration, e.g. using filters, frits, membranes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5023—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures with a sample being transported to, and subsequently stored in an absorbent for analysis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/06—Auxiliary integrated devices, integrated components
- B01L2300/0681—Filter
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0809—Geometry, shape and general structure rectangular shaped
- B01L2300/0825—Test strips
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/04—Moving fluids with specific forces or mechanical means
- B01L2400/0403—Moving fluids with specific forces or mechanical means specific forces
- B01L2400/0406—Moving fluids with specific forces or mechanical means specific forces capillary forces
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
- C12Q2565/60—Detection means characterised by use of a special device
- C12Q2565/625—Detection means characterised by use of a special device being a nucleic acid test strip device, e.g. dipsticks, strips, tapes, CD plates
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Clinical Laboratory Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762563314P | 2017-09-26 | 2017-09-26 | |
| US62/563,314 | 2017-09-26 | ||
| US201762609086P | 2017-12-21 | 2017-12-21 | |
| US62/609,086 | 2017-12-21 | ||
| PCT/US2018/052891 WO2019067567A1 (en) | 2017-09-26 | 2018-09-26 | DEVICES, SYSTEMS AND METHODS FOR BIOMARKER ANALYSIS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3076809A1 true CA3076809A1 (en) | 2019-04-04 |
Family
ID=65903224
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3076809A Pending CA3076809A1 (en) | 2017-09-26 | 2018-09-26 | Devices, systems and methods for biomarker analysis |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20200263167A1 (enExample) |
| EP (1) | EP3688158A4 (enExample) |
| JP (1) | JP2020534873A (enExample) |
| KR (1) | KR20200083461A (enExample) |
| CN (1) | CN111406107A (enExample) |
| AU (1) | AU2018342449A1 (enExample) |
| CA (1) | CA3076809A1 (enExample) |
| WO (1) | WO2019067567A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI833715B (zh) | 2017-10-27 | 2024-03-01 | 美商奇諾診療公司 | 用於超低體積液體生物檢體之裝置、系統及方法 |
| EP3517957B1 (en) | 2018-01-24 | 2019-12-18 | Midge Medical GmbH | Testing assembly and testing device for lateral flow assay |
| CA3095030A1 (en) | 2018-03-30 | 2019-10-03 | Juno Diagnostics, Inc. | Deep learning-based methods, devices, and systems for prenatal testing |
| AU2020354484A1 (en) * | 2019-09-23 | 2022-05-19 | Gateway Genomics, Llc | Methods, compositions, and kits for determining the sex of a fetus |
| CA3162239A1 (en) * | 2019-11-27 | 2021-06-03 | Juno Diagnostics, Inc. | Systems and devices for sample preparation and analyte detection |
| DE102020109744A1 (de) * | 2020-04-07 | 2021-10-07 | Midge Medical Gmbh | System und Vorrichtung zum Analysieren einer Probe |
| US20220042085A1 (en) * | 2020-08-07 | 2022-02-10 | Genalyze LLC | System and method of nucleic acid amplification for point of collection |
| EP3967772A1 (en) * | 2020-09-14 | 2022-03-16 | Ducrest, Percevent | Tools & methods usefool for detection of lactose intolerance and uses thereof |
| US20240018585A1 (en) * | 2020-12-15 | 2024-01-18 | Gateway Genomics, Llc | Methods, compositions, and devices for the rapid determination of fetal sex |
| US11964121B2 (en) | 2021-10-13 | 2024-04-23 | Satio, Inc. | Mono dose dermal patch for pharmaceutical delivery |
| US11877848B2 (en) | 2021-11-08 | 2024-01-23 | Satio, Inc. | Dermal patch for collecting a physiological sample |
| US11452474B1 (en) | 2021-04-14 | 2022-09-27 | Satio, Inc. | Dual lever dermal patch system |
| US11510602B1 (en) | 2021-11-08 | 2022-11-29 | Satio, Inc. | Dermal patch for collecting a physiological sample |
| US12053284B2 (en) | 2021-11-08 | 2024-08-06 | Satio, Inc. | Dermal patch for collecting a physiological sample |
| US12023156B2 (en) | 2021-10-13 | 2024-07-02 | Satio, Inc. | Dermal patch for collecting a physiological sample |
| US12214346B2 (en) | 2021-10-13 | 2025-02-04 | Satio, Inc. | Dermal patch with a diagnostic test strip |
| US12048543B2 (en) | 2021-11-08 | 2024-07-30 | Satio, Inc. | Dermal patch for collecting a physiological sample with removable vial |
| EP4322834A1 (en) * | 2021-04-14 | 2024-02-21 | Satio, Inc. | Self-contained dermal patch for detection of physiological analytes |
| US12178979B2 (en) | 2021-10-13 | 2024-12-31 | Satio, Inc. | Dermal patch for delivering a pharmaceutical |
| CA3220201A1 (en) * | 2021-06-02 | 2022-12-08 | Jose ZEVALLOS | Systems and methods for multimodal analysis of surgical drain fluid using interchangeable and customizable nucleic acid based tests |
| US12152280B2 (en) | 2021-09-20 | 2024-11-26 | Droplet Biosciences, Inc. | Drain fluid for diagnostics |
| WO2023147557A2 (en) * | 2022-01-28 | 2023-08-03 | The Johns Hopkins University | Bio-engineered enzymes and uses thereof |
| CN221028439U (zh) * | 2022-09-30 | 2024-05-28 | 台达电子国际（新加坡）私人有限公司 | 可携式核酸检测装置 |
| US12435357B2 (en) | 2022-12-22 | 2025-10-07 | Kanso Diagnostics Ltd. | Diagnostic device for detecting a target nucleic acid molecule in a biological sample |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1570090A4 (en) * | 2002-12-12 | 2008-01-23 | Novartis Vaccines & Diagnostic | DEVICE FOR STORING BIOLOGICAL SAMPLES AND PROCESS FOR DETECTING POSSIBLE CONTAMINATION OF BIOLOGICAL SAMPLES |
| EP1635700B1 (en) * | 2003-06-13 | 2016-03-09 | Sanofi-Aventis Deutschland GmbH | Apparatus for a point of care device |
| US20080113357A1 (en) * | 2006-06-29 | 2008-05-15 | Millipore Corporation | Filter device for the isolation of a nucleic acid |
| FR2923151B1 (fr) * | 2007-11-02 | 2010-09-03 | Commissariat Energie Atomique | Dispositif de prelevement sanguin comportant au moins un filtre . |
| EP2271772B1 (en) * | 2008-03-11 | 2014-07-16 | Sequenom, Inc. | Nucleic acid-based tests for prenatal gender determination |
| EP2113574A1 (en) * | 2008-04-28 | 2009-11-04 | Biotype AG | Substances and methods for a DNA based profiling assay |
| WO2011053790A2 (en) * | 2009-10-30 | 2011-05-05 | Fluidigm Corporation | Assay of closely linked targets in fetal diagnosis and coincidence detection assay for genetic analysis |
| WO2011063324A2 (en) * | 2009-11-20 | 2011-05-26 | The General Hospital Corporation | Microfluidic systems for isolating microvesicles |
| EP2516677B1 (en) * | 2009-12-23 | 2014-11-26 | Genetic Technologies Limited | Methods of enriching and detecting fetal nucleic acids |
| ES2565805T3 (es) * | 2010-11-09 | 2016-04-07 | Seventh Sense Biosystems, Inc. | Sistemas e interfaces para el muestreo de sangre |
| WO2012174256A2 (en) * | 2011-06-17 | 2012-12-20 | The Regents Of The University Of Michigan | Dna methylation profiles in cancer |
| PL2676606T3 (pl) * | 2012-06-20 | 2017-10-31 | Fabpulous B V | Szybko testujące urządzenie i sposób |
| US10262107B1 (en) * | 2013-03-15 | 2019-04-16 | Bao Tran | Pharmacogenetic drug interaction management system |
| US9644232B2 (en) * | 2013-07-26 | 2017-05-09 | General Electric Company | Method and device for collection and amplification of circulating nucleic acids |
| US10472620B2 (en) * | 2014-07-01 | 2019-11-12 | General Electric Company | Method, substrate and device for separating nucleic acids |
| CA2991918A1 (en) * | 2014-07-11 | 2016-01-14 | Advanced Theranostics Inc. | Point of care polymerase chain reaction device for disease detection |
| US10335078B2 (en) * | 2014-08-04 | 2019-07-02 | General Electric Company | Device for separation and collection of plasma |
| US10913068B2 (en) * | 2015-03-13 | 2021-02-09 | Nanyang Technological University | Testing device, microfluidic chip and nucleic acid testing method |
| TW201703754A (zh) * | 2015-05-25 | 2017-02-01 | 卡尤迪生物科技（北京）有限公司 | 用於樣品收集的裝置和方法 |
| ES2912965T3 (es) * | 2015-09-09 | 2022-05-30 | Drawbridge Health Inc | Dispositivos para la recopilación, estabilización y conservación de muestras |
| US10508300B2 (en) * | 2015-09-18 | 2019-12-17 | Vanadis Diagnostics | Probe set for analyzing a DNA sample and method for using the same |
| WO2017136430A1 (en) * | 2016-02-01 | 2017-08-10 | The Board Of Trustees Of The Leland Stanford Junior University | Exosome-total-isoloation-chip (exotic) device for isolation of exosome-based biomarkers |
| US11399755B2 (en) * | 2016-08-24 | 2022-08-02 | Becton, Dickinson And Company | Device for obtaining a blood sample |
| PL3336197T3 (pl) * | 2016-12-16 | 2022-08-08 | Eurofins Genomics Europe Sequencing GmbH | Markery epigenetyczne oraz powiązane sposoby i środki wykrywania i leczenia raka jajnika |
| CN106978486A (zh) * | 2017-03-24 | 2017-07-25 | 刘长胜 | 无细胞dna作为癌症免疫药物疗效评价的分子靶标及其应用 |
-
2018
- 2018-09-26 WO PCT/US2018/052891 patent/WO2019067567A1/en not_active Ceased
- 2018-09-26 AU AU2018342449A patent/AU2018342449A1/en not_active Abandoned
- 2018-09-26 EP EP18860060.5A patent/EP3688158A4/en not_active Withdrawn
- 2018-09-26 CN CN201880076253.3A patent/CN111406107A/zh active Pending
- 2018-09-26 US US16/648,819 patent/US20200263167A1/en not_active Abandoned
- 2018-09-26 JP JP2020538774A patent/JP2020534873A/ja active Pending
- 2018-09-26 CA CA3076809A patent/CA3076809A1/en active Pending
- 2018-09-26 KR KR1020207011988A patent/KR20200083461A/ko not_active Ceased
-
2021
- 2021-12-10 US US17/547,920 patent/US20220119801A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20200263167A1 (en) | 2020-08-20 |
| AU2018342449A1 (en) | 2020-04-16 |
| KR20200083461A (ko) | 2020-07-08 |
| US20220119801A1 (en) | 2022-04-21 |
| WO2019067567A1 (en) | 2019-04-04 |
| EP3688158A1 (en) | 2020-08-05 |
| CN111406107A (zh) | 2020-07-10 |
| EP3688158A4 (en) | 2021-06-16 |
| JP2020534873A (ja) | 2020-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220119801A1 (en) | Devices, systems and methods for biomarker analysis | |
| US11525134B2 (en) | Devices, systems and methods for ultra-low volume liquid biopsy | |
| US20220162591A1 (en) | Optimized ultra-low volume liquid biopsy methods, systems, and devices | |
| US20220170915A1 (en) | Digital health ecosystem | |
| Board et al. | Isolation and extraction of circulating tumor DNA from patients with small cell lung cancer | |
| Hyun et al. | Salivary exosome and cell-free DNA for cancer detection | |
| Sereno et al. | Isothermal nucleic acid amplification to detect infection caused by parasites of the Trypanosomatidae family: A literature review and opinion on the laboratory to field applicability | |
| Tungwiwat et al. | Development and Application of a Real‐Time Quantitative PCR for Prenatal Detection of Fetal α0‐Thalassemia from Maternal Plasma | |
| Mestry et al. | Key methodological challenges in detecting circulating miRNAs in different biofluids | |
| Uchiyama et al. | Understanding quantitative polymerase chain reaction bioanalysis issues before validation planning: Japan Bioanalysis Forum discussion group | |
| US20220404353A1 (en) | Systems and devices for sample preparation and analyte detection | |
| Yen et al. | Technical considerations and protocol optimization for neonatal salivary biomarker discovery and analysis | |
| Maron et al. | Comparative performance analyses of commercially available products for salivary collection and nucleic acid processing in the newborn | |
| Liu et al. | Primer-introduced restriction analysis polymerase chain reaction method for non-invasive prenatal testing of β-thalassemia | |
| Jouannic et al. | Very early prenatal diagnosis of genetic diseases based on coelomic fluid analysis: a feasibility study | |
| Alhur et al. | Fetal nucleated red blood cells preferable than cell-free fetal DNA for early determination of gender among invasive and non-invasive source using novel four genes multiplex PCR | |
| Chadud et al. | Assessment of free fetal DNA concentration in maternal plasma during the first trimester of pregnancy: comparative study between EDTA and PPT tubes–pilot study |